Outlook Therapeutics(OTLK.US)湿性AMD疗法ONS-5010临床试验未达到主要终点

智通财经11-27

智通财经APP获悉，Outlook Therapeutics(OTLK.US)表示，其用于治疗湿性年龄相关性黄斑变性(AMD)眼部疾病的研究性疗法ONS-5010的临床试验未能达到主要终点，受此影响，该股周三盘前暴跌约82%。这家总部位于新泽西州伊塞林的生物技术公司援引其NORSE EIGHT试验的顶线数据表示，ONS-5010(也称为Lytenava)在大约两个月后没有达到预先指定的非劣效性终点...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486382635?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-27 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486382635","market":"hk","top_or_hot":-1,"title":"Outlook Therapeutics(OTLK.US)湿性AMD疗法ONS-5010临床试验未达到主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，Outlook Therapeutics(OTLK.US)表示，其用于治疗湿性年龄相关性黄斑变性(AMD)眼部疾病的研究性疗法ONS-5010的临床试验未能达到主要终点，受此影响，该股周三盘前暴跌约82%。这家总部位于新泽西州伊塞林的生物技术公司援引其NORSE EIGHT试验的顶线数据表示，ONS-5010(也称为Lytenava)在大约两个月后没有达到预先指定的非劣效性终点...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1216882.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics(OTLK.US)湿性AMD疗法ONS-5010临床试验未达到主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics(OTLK.US)湿性AMD疗法ONS-5010临床试验未达到主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 20:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1216882.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，Outlook Therapeutics(OTLK.US)表示，其用于治疗湿性年龄相关性黄斑变性(AMD)眼部疾病的研究性疗法ONS-5010的临床试验未能达到主要终点，受此影响，该股周三盘前暴跌约82%。这家总部位于新泽西州伊塞林的生物技术公司援引其NORSE EIGHT试验的顶线数据表示，ONS-5010(也称为Lytenava)在大约两个月后没有达到预先指定的非劣效性终点...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1216882.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4512","symbol_name":"苹果概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1216882.html","article_id":"2486382635","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486382635","pubTimestamp":1732711387,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，Outlook Therapeutics表示，其用于治疗湿性年龄相关性黄斑变性眼部疾病的研究性疗法ONS-5010的临床试验未能达到主要终点，受此影响，该股周三盘前暴跌约82%。这家总部位于新泽西州伊塞林的生物技术公司援引其NORSE EIGHT试验的顶线数据表示，ONS-5010在大约两个月后没有达到预先指定的非劣效性终点。8月，美国食品药品监督管理局拒绝批准ONS-5010用于湿性AMD，理由是具体的生产问题和需要额外的临床证据。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4512":"苹果概念","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4529":"IDC概念","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","BK4554":"元宇宙及AR概念","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4532":"文艺复兴科技持仓","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LENZ":"Therapeutics","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","BK4139":"生物科技","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","03347":"泰格医药","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","BK4566":"资本集团","BK4575":"芯片概念","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","OTLK":"Outlook Therapeutics, Inc.","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","BK4141":"半导体产品","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","GFS":"GLOBALFOUNDRIES Inc.","BK4573":"虚拟现实"},"translate_title":"Outlook Therapeutics (OTLK.US) wet AMD therapy ONS-5010 clinical trial failed to meet primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":1,"03347":1,"LENZ":1,"GFS":1},"content_text":"智通财经APP获悉，Outlook Therapeutics(OTLK.US)表示，其用于治疗湿性年龄相关性黄斑变性(AMD)眼部疾病的研究性疗法ONS-5010的临床试验未能达到主要终点，受此影响，该股周三盘前暴跌约82%。这家总部位于新泽西州伊塞林的生物技术公司援引其NORSE EIGHT试验的顶线数据表示，ONS-5010(也称为Lytenava)在大约两个月后没有达到预先指定的非劣效性终点。然而，Outlook注意到该药物具有生物活性、视力改善和良好的安全性，并称计划在完成数据分析后，于2025年第一季度在美国重新提交ONS-5010的上市申请。NORSE EIGHT的数据分析目前正在进行中，预计该研究的三个月数据将于明年1月公布。8月，美国食品药品监督管理局(FDA)拒绝批准ONS-5010用于湿性AMD，理由是具体的生产问题和需要额外的临床证据。然而，该公司计划明年在欧盟和英国推出该药物，Lytenava已经在这两个地区获得了治疗湿性AMD的许可。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486382635"}